JGC
PRAX icon

J. Goldman & Co’s Praxis Precision Medicines PRAX Stock Holding History

J. Goldman & Co’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.01M Sell
9,000
-4,600
-34% -$1.46M 0.08% 285
2026
Q1 		$4.38M Buy
13,600
+5,500
+68% +$1.7M 0.13% 205
2025
Q4 		$2.39M Buy
+8,100
New +$1.51M 0.06% 295

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

J. Goldman & Co's PRAX Position: Q2 2026 in Review

J. Goldman & Co increased its Praxis Precision Medicines (PRAX) stake by 3.3% in Q2 2026, buying an estimated $165K and bringing the position to 16,186 shares worth $5.42M. The position accounts for 0.14% of the portfolio, ranked #191.

J. Goldman & Co first reported a position in PRAX in Q1 2023 and has held it in 9 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • J. Goldman & Co held 16,186 shares of Praxis Precision Medicines worth $5.42M as of Q2 2026.
  • J. Goldman & Co bought 522 Praxis Precision Medicines shares in Q2 2026, an estimated $165K.
  • Praxis Precision Medicines made up 0.14% of J. Goldman & Co's portfolio in Q2 2026, its #191 holding.
  • J. Goldman & Co first reported a position in Praxis Precision Medicines in Q1 2023 and has held it in 9 quarters since.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.